Equities researchers at Oppenheimer initiated coverage on shares of Clearside Biomedical (NASDAQ:CLSD – Get Free Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $5.00 price target on the stock. Oppenheimer’s price objective suggests a potential upside of 313.22% from the company’s current price.
Several other equities research analysts have also recently issued reports on the stock. HC Wainwright lowered their price objective on shares of Clearside Biomedical from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, May 13th. StockNews.com lowered Clearside Biomedical from a “hold” rating to a “sell” rating in a research report on Friday, May 10th. JMP Securities reissued a “market outperform” rating and set a $5.00 price target on shares of Clearside Biomedical in a research report on Wednesday, March 13th. Wedbush restated an “outperform” rating and issued a $4.00 price objective (down from $5.00) on shares of Clearside Biomedical in a report on Wednesday, March 13th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $4.00 target price on shares of Clearside Biomedical in a report on Monday, May 13th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $4.60.
View Our Latest Stock Report on Clearside Biomedical
Clearside Biomedical Trading Down 3.2 %
Clearside Biomedical (NASDAQ:CLSD – Get Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The company had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.98 million. During the same period in the prior year, the firm posted ($0.15) EPS. Analysts predict that Clearside Biomedical will post -0.63 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Clearside Biomedical
A number of large investors have recently added to or reduced their stakes in the company. Rosalind Advisors Inc. purchased a new position in shares of Clearside Biomedical in the 1st quarter worth approximately $3,967,000. Vanguard Group Inc. grew its holdings in Clearside Biomedical by 14.5% in the first quarter. Vanguard Group Inc. now owns 2,490,796 shares of the company’s stock worth $3,811,000 after purchasing an additional 314,480 shares during the last quarter. International Assets Investment Management LLC acquired a new position in shares of Clearside Biomedical during the first quarter worth $57,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Clearside Biomedical during the 1st quarter valued at $49,000. 18.75% of the stock is currently owned by institutional investors.
About Clearside Biomedical
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Featured Articles
- Five stocks we like better than Clearside Biomedical
- Insider Buying Explained: What Investors Need to Know
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- Stock Market Upgrades: What Are They?
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Stock Splits, Do They Really Impact Investors?
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.